Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT06055075
- Locations
- 🇰🇷
Seoul St Mary's Hospital, Seoul, Korea, Republic of
🇦🇺Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT06047080
- Locations
- 🇩🇪
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany
🇺🇸Kaiser Permanente Medical Ctr, Vallejo, California, United States
🇺🇸St. Luke's Hospital, Chesterfield, Missouri, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 295
- Registration Number
- NCT06004245
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸Norton Cancer Institute - MDC, Louisville, Kentucky, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05987449
- Locations
- 🇺🇸
Georgetown Uni Medical Center; Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸Indiana Hemophilia & Thrombosis center, Indianapolis, Indiana, United States
🇺🇸University of Iowa Hospitals and Clnics Dept of Pediatrics, Iowa City, Iowa, United States
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 120
- Registration Number
- NCT05987423
- Locations
- 🇺🇸
Eye Associates of New Mexico, Tucumcari, New Mexico, United States
🇺🇸'Northwell Health Physician Partners Ophthalmology, Great Neck, New York, United States
🇺🇸Thrive Health Research LLC, Beverly Hills, California, United States
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT05954910
- Locations
- 🇨🇳
Third Xiangya Hospital of Central South University, Changsha, China
🇨🇳Xiangya Hospital of Centre-South University, Changsha, China
🇨🇳The Affiliated Hospital Of Qingdao University, Qingdao, China
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT05949580
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 178
- Registration Number
- NCT05945927
- Locations
- 🇨🇳
Beijing Hospital; Internal Medicine-Oncology, Beijing, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China
🇨🇳Jiangmen Central Hospital, Jiangmen, China
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT05924243
- Locations
- 🇳🇱
Brain Research Center B.V, Amsterdam, Netherlands
🇳🇱UMC St Radboud, Nijmegen, Netherlands
🇳🇱Brain Research Center Zwolle, Zwolle, Netherlands
RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT05910528
- Locations
- 🇸🇰
Gastro Ambulancia - Endomed, Košice, Slovakia
🇭🇺Clinexpert Kft., Budapest, Hungary
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States